Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Short Interest Down 80.4% in March

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the target of a significant decline in short interest in the month of March. As of March 31st, there was short interest totaling 42,085 shares, a decline of 80.4% from the March 15th total of 214,479 shares. Approximately 2.7% of the shares of the company are sold short. Based on an average daily volume of 132,132 shares, the short-interest ratio is presently 0.3 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Catheter Precision stock. Millennium Management LLC acquired a new position in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned 2.08% of Catheter Precision at the end of the most recent reporting period. 20.34% of the stock is owned by institutional investors and hedge funds.

Catheter Precision Trading Up 2.5%

Shares of NYSEAMERICAN:VTAK traded up $0.03 during trading on Monday, reaching $1.22. The company had a trading volume of 162,278 shares, compared to its average volume of 214,746. The stock’s fifty day moving average price is $1.41 and its 200 day moving average price is $1.95. Catheter Precision has a fifty-two week low of $0.85 and a fifty-two week high of $15.68. The company has a current ratio of 0.10, a quick ratio of 0.08 and a debt-to-equity ratio of 0.46.

Catheter Precision Company Profile

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.